Articles

  • 1 week ago | en.globes.co.il | Richard Francis |Gali Weinreb

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) held an "Innovation and Strategy Day" today, in which it discussed the future of its (non-generic) biopharmaceutical activity. The company sees revenue from its three leading drugs: Austedo, for treating involuntary movements; migraine prevention treatment Ajovy; and long-acting schizophrenia treatment Uzedy, reaching at least $5 billion by 2030. This compares with $2 billion for the three products combined in 2024.

  • 1 week ago | en.globes.co.il | Gali Weinreb

    Israeli universities do not generally disclose the lists of their donors and how much they have raised, but in the past year three of them boasted especially high contributions. The latest was Tel Aviv University.

  • 1 week ago | en.globes.co.il | Gali Weinreb

    Apartments sold and rented Israel claims Sanaa Airport out of action With the EU discussing proposals to end Israel's participation in the Horizon program, and the Trump administration cutting international grants, Israeli researchers fear for the future. Israel's exclusion from the EU's Horizon Europe research and innovation program and its support for science, as is being discussed, would set Israeli science back years and relegate its status.

  • 3 weeks ago | en.globes.co.il | Gali Weinreb

    Is Nice ready to bounce back? Iron Beam - world's most powerful laser defense system Over the past 15 years, Israeli startups have been applying Big Data to cure the US healthcare system’s ills. How do they do it, and can they maintain their advantage? Israel’s biomedical industry is undergoing among its most difficult periods, but two sub-sectors are still managing to keep their heads above water.

  • 3 weeks ago | en.globes.co.il | Gali Weinreb

    US diagnostics giant Qiagen has announced that it has signed a definitive agreement to acquire Israeli AI software company Genoox for $80 million, including an immediate payment of $70 million and a further $10 million in milestone payments. Genoox, which has 55 employees, will become Qiagen's Israel development center and will expand by hiring more development and software staff.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →